CSTL: TissueCypher and DecisionDx tests drive growth, with AI and reimbursement advances supporting expansion
Strong growth in molecular diagnostics, especially TissueCypher, is supported by robust margins and AI-driven innovation. Dermatology and gastroenterology segments are expanding, with new product launches and ongoing reimbursement progress. Long-term market penetration and payer adoption remain key…